Explore
Validate
LearnPA5-38014
antibody from Invitrogen Antibodies
Targeting: PROM1
AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [3]
- Immunocytochemistry [5]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-38014 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD133 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A recommended positive control is Jurkat cell lysate. Multiple isoforms of PROM1 are known to exist.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- 4° C
Submitted references Organ-specific extracellular matrix directs trans-differentiation of mesenchymal stem cells and formation of salivary gland-like organoids in vivo.
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.
miR-200b inhibits CD133(+) glioma cells by targeting the AKT pathway.
LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4.
Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro.
Tran ON, Wang H, Li S, Malakhov A, Sun Y, Abdul Azees PA, Gonzalez AO, Cao B, Marinkovic M, Singh BB, Dean DD, Yeh CK, Chen XD
Stem cell research & therapy 2022 Jul 15;13(1):306
Stem cell research & therapy 2022 Jul 15;13(1):306
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.
Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, Ji T, Zhang H, Dong W, Jin X, Chen D, Li Y, Zhang S, Xie HQ, Zhao B, Zhao T, Lu J, Hu ZW, Cao X, Qin FX, Huang B
Nature communications 2017 May 10;8:15207
Nature communications 2017 May 10;8:15207
miR-200b inhibits CD133(+) glioma cells by targeting the AKT pathway.
Liu A, Yu Q, Peng Z, Huang Y, Diao S, Cheng J, Wang W, Hong M
Oncology letters 2017 Jun;13(6):4701-4707
Oncology letters 2017 Jun;13(6):4701-4707
LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4.
Han S, Wang C, Qin X, Xia J, Wu A
Journal of experimental & clinical cancer research : CR 2017 Jun 22;36(1):83
Journal of experimental & clinical cancer research : CR 2017 Jun 22;36(1):83
Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro.
Bryukhovetskiy I, Lyakhova I, Mischenko P, Milkina E, Zaitsev S, Khotimchenko Y, Bryukhovetskiy A, Polevshchikov A, Kudryavtsev I, Khotimchenko M, Zhidkov M
Oncology letters 2017 Feb;13(2):738-746
Oncology letters 2017 Feb;13(2):738-746
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of CD133/Prominin-1 in Jurkat cell lysate using a CD133/Prominin-1 polyclonal antibody (Product # PA5-38014) at a dilution of 1 µg/mL in (A) the absence and (B) the presence of a blocking peptide.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of PROM1 in Jurkat cell lysate with CD133 Polyclonal Antibody (Product # PA5-38014) at 1 µg/mL in (A) the absence and (B) the presence of blocking peptide.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot was performed using Anti-CD133 Polyclonal Antibody (Product # PA5-38014) and a 133 kDa band corresponding to Prominin-1 was observed across cell lines and tissue tested, with low expression in HeLa which is reported in the literature. Additional multiple uncharacterized bands (*) were observed across the panel. Membrane enriched extracts (30 µg lysate) of Caco-2 (Lane 1), HT-29 (Lane 2), HeLa (Lane 3), and Mouse Kidney (Lane 4) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP0321BOX). Resolved proteins were then transferred onto a Nitrocellulose membrane (Product # IB23002) by iBlot® 2 Dry Blotting System (Product # IB21001). The Blot was probed with the primary antibody (1 µg/mL) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry analysis of CD133/Prominin-1 in Jurkat cells using a CD133/Prominin-1 polyclonal antibody (Product # PA5-38014) at a dilution of 2.5 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of CD133/Prominin-1 in Jurkat cells using a CD133/Prominin-1 polyclonal antibody (Product # PA5-38014) at a dilution of 20 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence of PROM1 in Jurkat cells with CD133 Polyclonal Antibody (Product # PA5-38014) at 20 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry of PROM1 in Jurkat cells with CD133 Polyclonal Antibody (Product # PA5-38014) at 2.5 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence of PROM1 in Jurkat cells with CD133 Polyclonal Antibody (Product # PA5-38014) at 20 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
